Search

Search Constraints

You searched for: Author/Creator Yanagitani, Noriko

Search Results

1. A phase II study of carboplatin and pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. (2016)

2. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. (June 2020)

3. Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. (2020)

4. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Issue 10 (19th August 2019)

5. Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib. Issue 6 (7th May 2021)

6. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01). Issue 2 (21st November 2022)

7. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02). Issue 10 (12th April 2022)

8. Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2. Issue 6 (2nd February 2021)

9. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. (July 2019)

10. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Issue 9 (1st July 2013)